Dr Thomas Duthy, Executive Director of Neurotech said “We thank the Monash HREC for this extension,
which provides comfort to our Phase I/II trial participants that they are able to receive NTI164 therapy
for an additional 52 weeks above existing approvals. We continue to focus our resources on
completing the current Phase II/III ASD trial and remain on track to report the results of our Phase II/III
ASD trial in late Q1 CY2024 to early Q2 CY2024.”
- Forums
- ASX - By Stock
- NTI
- Ann: Neurotech Receives Additional HREC Approval in Autism
Ann: Neurotech Receives Additional HREC Approval in Autism, page-2
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NTI (ASX) to my watchlist
(20min delay)
|
|||||
Last
6.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $70.2M |
Open | High | Low | Value | Volume |
7.0¢ | 7.0¢ | 6.9¢ | $6.913K | 98.89K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 28417 | 6.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.0¢ | 156815 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 28417 | 0.069 |
2 | 48500 | 0.068 |
3 | 56841 | 0.067 |
1 | 75000 | 0.066 |
2 | 81035 | 0.065 |
Price($) | Vol. | No. |
---|---|---|
0.070 | 156815 | 2 |
0.071 | 17275 | 1 |
0.072 | 55000 | 1 |
0.073 | 13514 | 1 |
0.075 | 94637 | 2 |
Last trade - 10.17am 25/06/2024 (20 minute delay) ? |
Featured News
NTI (ASX) Chart |